Makaluvamine Analogues For Development As Anticancer Agents

Tech ID: 33160 / UC Case 2017-263-0


Marine sponges and microorganisms are the source of many promising bioactive products for use in the treatment of cancer. Multicompound libraries can be readily generated from these sources for comprehensive bioactivity and biosynthetic investigations. Prior studies into these organisms/communities involved examination of Zyzzya sponge metabolites and corresponding bacterial communities from this genus. One particularly potent compound was a makaluvamine extracted from a Zyzzya fulginosa sponge from Papua New Guinea was highly active on PANC-1 cells.  Additional studies show that the key structure of malakuvamine and other related compounds is a pyrrolo[4,3,2-de]quinoline motif now seen in 100 similar natural products. 

Technology Description

 This invention, made in collaboration with researchers at the Henry Ford Health System describes Pyrrolo[4,3,2-de]quinolines derived from malakuvamine and highly active against PANC-1 cells

 One particular analog, termed makulavamine J had an IC50 of 54 nM in PANC-1 cells and 120 nm in OVCAR-5 cells, while another analog, 15-O-acetyl makaluvamine J (structure above), had an IC50 of 81 nM in PANC-1 cells and an IC50 of 8.6 nM in OVCAR-5 cells. 


Potential lead in cancer therapy


Derived from a natural product

Intellectual Property Information

Country Type Number Dated Case
United States Of America Issued Patent 11,020,488 06/01/2021 2017-263
Patent Cooperation Treaty Published Application 2018/170019 09/20/2018 2017-263

Related Materials


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Crews, Phillip O.
  • Lin, Sheng
  • Tenney, Karen
  • Valeriote, Frederick A.

Other Information


makulavamine, natural products chemistry, marine derived drugs, natural product analogs

Categorized As